Stock AnalizBridgeBio Pharma (BBIO) earnings for the quarter ended September 2026: EPS beats estimates
BridgeBio Pharma reported results for the quarter ended September 2026 on October 29, 2026. Adjusted earnings per share came in at -$0.42 against the analysts’ average forecast of -$0.56, a beat of 24.6%.
Revenue for the quarter was $353 million, up 192.6% from $121 million in the same quarter a year earlier.
The market’s verdict: the stock rose 5.8% on the first trading day after the report.
The last four quarters
BridgeBio Pharma has beaten the analysts’ EPS forecast in 1 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | -$0.42 | -$0.56 | +24.6% | +193% | +5.8% |
| Jun 2026 | -$0.78 | -$0.58 | −33.9% | +120% | −0.9% |
| Mar 2026 | -$0.84 | -$0.62 | −36.2% | +67% | −1.0% |
| Dec 2025 | -$0.94 | -$0.62 | −50.6% | +2521% | −2.0% |
What comes next
Analysts expect EPS of -$0.50 for the next quarter on average and -$2.49 for the fiscal year ending December 31, 2026.
The average analyst price target is $106.85, 36% above the current price of $78.30.
Valuation and score
BridgeBio Pharma scores 1.2 out of 5 overall on Stock Analiz (weak). Full BridgeBio Pharma analysis with 10 years of financials
Frequently asked questions
What was BridgeBio Pharma’s EPS for the quarter ended September 2026?
-$0.42 adjusted per share, against an analyst consensus of -$0.56.
How much revenue did BridgeBio Pharma report?
$353 million, up 192.6% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.